Stockscreener 앱 받기
1.985
10.59%
-0.235
시간 외 거래:
2.07
0.085
+4.28%
전일 마감가:
$2.22
열려 있는:
$2.21
하루 거래량:
684.11K
Relative Volume:
7.18
시가총액:
$19.80M
수익:
-
순이익/손실:
$-34.77M
주가수익비율:
-0.5998
EPS:
-3.3097
순현금흐름:
$-29.79M
1주 성능:
-54.89%
1개월 성능:
-59.07%
6개월 성능:
-81.47%
1년 성능:
-83.67%
1일 변동 폭
$1.95
$2.21
1주일 범위
$1.95
$2.81
52주 변동 폭
$1.95
$19.35
Atossa Therapeutics Inc Stock (ATOS) Company Profile
명칭
Atossa Therapeutics Inc
전화
206.588.0256
주소
1448 NW MARKET STREET, SEATTLE, WA
Compare ATOS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
1.985 | 23.44M | 0 | -34.77M | -29.79M | -3.3097 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-01-26 | 개시 | Maxim Group | Buy |
Atossa Therapeutics Inc 주식(ATOS)의 최신 뉴스
Atossa Therapeutics brings medical innovation to Hudson Institute strategic discussions - Traders Union
Atossa Therapeutics (ATOS) Q1 2026 Earnings: Narrowing Losses with Positive EPS SurpriseRevenue Warning Signal - newsline.com
Atossa Therapeutics closes $4.5M registered direct offering By Investing.com - Investing.com Australia
Atossa Therapeutics closes $4.5M registered direct offering - Investing.com UK
Cancer-drug developer Atossa raises $4.5M, eyes $12M more - Stock Titan
Atossa Therapeutics Announces Up To $16.5 Million Registered Direct Offering - Pulse 2.0
Atossa Therapeutics examines biosecurity and scientific innovation after COVID 19 lessons - Traders Union
Atossa Therapeutics (NASDAQ: ATOS) sells 1.36M shares with warrants in $4.5M deal - Stock Titan
Atossa Therapeutics prices up to $16.5M direct offering - MSN
Market Movers | Winners: XXII, PPCB, CCHH | Losers: BCPC, ATOS, BATL - Trefis
Atossa Therapeutics, Inc. (ATOS) Latest Stock News & Headlines - Yahoo Finance
Top Midday Decliners - Moomoo
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings - Benzinga
Dow Jumps Over 250 Points; US Initial Jobless Claims RiseAtossa Therapeutics (NASDAQ:ATOS), Big Tree C - Benzinga
Atossa Therapeutics Launches $16.5 Million Registered Direct Offering - marketscreener.com
Atossa Therapeutics stock tumbles on $4.5M stock offering - Investing.com UK
Atossa Therapeutics Announces Registered Direct Offering and Warrants - TipRanks
Atossa Therapeutics stock tumbles on $4.5M stock offering By Investing.com - Investing.com UK
Atossa Therapeutics raises $4.5M in registered direct offering - Investing.com
Atossa Therapeutics raises $4.5M in registered direct offering By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Atossa Therapeutics Prices Registered Direct Offering at $3.30, Netting About $4.1 Million - TradingView
Atossa Therapeutics (ATOS) prices $3.30 registered direct stock and warrant sale - Stock Titan
Biotech Atossa targets up to $16.5M to fund clinical work - Stock Titan
ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits
Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment - Proactive financial news
Atossa Therapeutics (ATOS) Climbs 1.79% as Shares Approach Key Resistance at $4.78Wedge Breakout - newsline.com
Lowering mammographic breast density could cut future cancer risk, ATOSSA THERAPEUTICS, INC. asserts - Traders Union
CEO Chat with Steven Quay, MD, PhD, Chairman, President, & CEO of Atossa Therapeutics - Yahoo Finance
Atossa Therapeutics (ATOS) Edges Higher on Modest Gains, Holds Above Key SupportReversal Trade - The Legal Advocate
ATOS News | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
Cash from investing activities of Atossa Therapeutics, Inc. – DUS:YAG - TradingView
Atossa Therapeutics (ATOS) Highlights Promising Data for (Z)-End - GuruFocus
Atossa presents preclinical data on breast cancer drug at ASCO - Investing.com UK
Atossa Presents New Data Highlighting (Z)-Endoxifen's Potential in Breast Cancer - Intellectia AI
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial - PR Newswire
(Z)-Endoxifen hits ESR1 breast cancer mutations in new trial - Stock Titan
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
ATOS Stock Price, Quote & Chart | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
Atossa Therapeutics (ATOS) Holds Steady Near Support Amid Modest DeclineScalping Stock Signals - newsline.com
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy - BioSpace
Atossa Therapeutics advances research on Z-endoxifen for Duchenne muscular dystrophy - Traders Union
Atossa's New Research Findings on DMD - Intellectia AI
Atossa Therapeutics (ATOS) price target decreased by 47.43% to 23.46 - MSN
ATOS Should I Buy - Intellectia AI
Atossa Therapeutics (ATOS) director granted 10,000 RSUs vesting after 2026 - Stock Titan
ATOS (ATOS) director Stephen Galli receives 10,000 RSU equity grant - Stock Titan
Atossa Therapeutics (ATOS) director granted 10,000 RSUs in stock award - Stock Titan
Atossa (NASDAQ: ATOS) director awarded 10,000 RSUs in stock grant - Stock Titan
Atossa Therapeutics (ATOS) director granted 10,000-share RSU award - Stock Titan
Atossa Therapeutics Inc (ATOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):